BIOFRONTERA AG

(B8F)
  Rapport
Vertraagde tijd Xetra  -  17:36 27-06-2022
1.220 EUR   +2.09%
09/06Biofrontera AG benoemt Paul Böckmann tot lid van de Raad van Bestuur
CI
17/05Biofrontera AG maakt winstcijfers bekend voor het eerste kwartaal eindigend op 31 maart 2022
CI
13/05Earnings Flash (BFRI) BIOFRONTERA Posts Q1 Revenue $9.8M, vs. Street Est van $9.83M
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciënConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAndere talenPersberichtenOfficiële publicatiesSectornieuws
Communiqués de presse de la société BIOFRONTERA AG
08/06PTA-NEWS : Biofrontera AG: Biofrontera's license partner Louis Widmer receives an extensio..
PU
30/04PTA-NEWS : Biofrontera AG: Biofrontera reports results for the fiscal year 2021
PU
28/04PTA-NEWS : Biofrontera AG: Biofrontera shifts the publication of the Annual Report 2021 to..
PU
14/04PTA-NEWS : Biofrontera AG: Biofrontera announces conference call to be held on April 29, 2..
PU
04/04PTA-NEWS : Biofrontera AG: Governmental price decree for Ameluz® withdrawn in Spain
PU
04/04PTA-NEWS : Biofrontera AG: Statement of Biofrontera AG on the open letter of Maruho Deutsc..
PU
14/03PTA-NEWS : Biofrontera AG: Biofrontera improves the brand protection of Ameluz®-PDT in the..
PU
10/03BIOFRONTERA : files Form 15F to suspend SEC Reporting Requirements and starts trading Leve..
PU
09/03PTA-NEWS : Biofrontera AG: Biofrontera files Form 15F to suspend SEC Reporting Requirement..
PU
24/02BIOFRONTERA AG : Management Board and supervisory board are going to submit proposals for ..
PU
22/02BIOFRONTERA AG : Changes in the supervisory board - Form 6-K
PU
15/02BIOFRONTERA : decides to delist ADS from Nasdaq to reduce complexity and costs - Form 6-K
PU
14/02Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs
AQ
01/02BIOFRONTERA : announces progress of phase III study for the treatment of sBCC with Ameluz®..
PU
01/02PTA-NEWS : Biofrontera AG: Biofrontera AG announces progress of phase III study for the tr..
PU
13/01BIOFRONTERA : announces preliminary revenue figures for the full year 2021 - Form 6-K
PU
2021BIOFRONTERA : announces reduction of shareholding in Biofrontera Inc. below 50% - Form 6-K
PU
2021BIOFRONTERA AKTIENGESELLSCHAFT DECEM : 00 AM - Form 6-K
PU
2021PTA-NEWS : Biofrontera AG: Biofrontera AG announces results of the elections for the new S..
PU
2021BIOFRONTERA : enrolls first patient to phase IIb clinical study evaluating Ameluz® / BF-Rh..
PU
2021PTA-NEWS : Biofrontera AG: Biofrontera enrolls first patient to phase IIb clinical study e..
PU
2021BIOFRONTERA : obtains notice of allowance for US patent on PDT-lamp and treatment method -..
PU
2021PTA-NEWS : Biofrontera AG: Biofrontera AG obtains notice of allowance for US patent on PDT..
PU
2021PTA-NEWS : Biofrontera AG: Biofrontera enrolls first patient to phase I safety study evalu..
PU
2021BIOFRONTERA : obtains notice of allowance for US patent on innovative illumination protoco..
PU
2021PTA-NEWS : Biofrontera AG: Biofrontera obtains notice of allowance for US patent on innova..
PU
2021BIOFRONTERA : announces timing of the departure of the CEO - Form 6-K
PU
2021BIOFRONTERA AG : Biofrontera Inc. announces closing of USD15 million private placement - F..
PU
2021BIOFRONTERA : Form 6-K
PU
2021BIOFRONTERA AG : Biofrontera Inc. announces USD 15 million private placement - Form 6-K
PU
2021BIOFRONTERA : reaches out-of-court settlement with DUSA Pharmaceuticals, Inc - Form 6-K
PU
2021BIOFRONTERA : announces mediation results - Form 6-K
PU
2021Biofrontera AG announces mediation results
AQ
2021BIOFRONTERA : Quarterly report Q3 2021 - Form 6-K
PU
2021Biofrontera reports financial results for the third quarter and nine months ended Septe..
GL
2021BIOFRONTERA : announces initiation of clinical studies - Form 6-K
PU
2021PTA-NEWS : Biofrontera AG: Biofrontera AG announces initiation of clinical studies
PU
2021Biofrontera AG announces initiation of clinical studies
AQ
2021CEO seeks early retirement from the Management Board - Form 6-K
PU
2021BIOFRONTERA AG : Conference call to discuss third quarter 2021 financial results to be hel..
PU
2021PTA-NEWS : Biofrontera AG: Conference call to discuss third quarter 2021 financial results..
PU
2021BIOFRONTERA AG : Conference call to discuss third quarter 2021 financial results to be hel..
GL
2021BIOFRONTERA AG : Conference call to discuss third quarter 2021 financial results to be hel..
GL
2021Early repayment of EIB loan - Form 6-K
PU
2021Biofrontera is setting the path for further expansion in the world's largest pharmaceut..
PU
2021Biofrontera Inc. closes IPO - Form 6-K
PU
2021PTA-NEWS : Biofrontera AG: Biofrontera is setting the path for further expansion in the U...
PU
2021Initial public offering price of Biofrontera Inc. IPO - Form 6-K
PU
2021Biofrontera AG approves modification of the US-IPO of Biofrontera Inc - Form 6-K
PU
2021BIOFRONTERA : receives FDA-approval of the BF-RhodoLED® XL lamp - Form 6-K
PU
2021BIOFRONTERA AG : receives FDA-approval of the BF-RhodoLED® XL lamp
AQ
2021BIOFRONTERA : reports preliminary approximate revenues for the month of September 2021 (Fo..
PU
2021BIOFRONTERA : Leverkusen, Germany, October 1, 2021 – Biofrontera AG currently holds ..
PU
2021PTA-NEWS : Biofrontera AG: Biofrontera reports preliminary approximate revenues for the mo..
PU
2021Biofrontera reports preliminary approximate revenues for the month of September 2021
GL
2021BIOFRONTERA : reports preliminary approximate revenues for the month of September 2021
GL
2021BIOFRONTERA : reports preliminary revenue for the month of August 2021 (Form 6-K)
PU
2021PTA-NEWS : Biofrontera AG: Biofrontera reports preliminary revenue for the month of August..
PU
2021BIOFRONTERA : reports preliminary revenue for the month of August 2021
AQ
2021BIOFRONTERA : reports financial results for the six months ended June 30, 2021 (Form 6-K)
PU
2021PTA-NEWS : Biofrontera AG: Biofrontera reports financial results for the six months ended ..
PU
2021Biofrontera reports financial results for the six months ended June 30, 2021
GL
2021BIOFRONTERA AG : Conference call to discuss half-year 2021 financial results to be held on..
PU
2021PTA-NEWS : Biofrontera AG: Conference call to discuss half-year 2021 financial results to ..
PU
2021BIOFRONTERA AG : Conference call to discuss half-year 2021 financial results to be held on..
AQ
2021BIOFRONTERA : reports preliminary revenue for the month of July 2021
AQ
2021PTA-NEWS : Biofrontera AG: Biofrontera enters into license and supply agreement with Medac..
PU
2021Biofrontera enters into license and supply agreement with Medac for the marketing of Am..
GL
2021BIOFRONTERA : Leverkusen, Germany, July 6, 2021 – Biofrontera AG currently holds 100..
PU
2021Biofrontera Inc. seeks IPO in the USA
GL
2021BIOFRONTERA : reports preliminary revenue for the month of June 2021 (Form 6-K)
PU
2021PTA-NEWS : Biofrontera AG: Biofrontera reports preliminary revenue for the month of June 2..
PU
2021Biofrontera reports preliminary revenue for the month of June 2021
GL
2021BIOFRONTERA : provides update on clinical developments (Form 6-K)
PU
2021PTA-NEWS : Biofrontera AG: Biofrontera provides update on clinical developments
PU
1  2  3  4  5  6  7  8Volgende